Form 4: Nektar R&D Chief Granted Equity Awards

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, received a grant of 6,250 restricted stock units and 25,000 stock options, vesting over four years.

Summary

• Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, was granted equity awards.
• The awards include 6,250 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• Also granted were 25,000 stock options with an exercise price of $43.48 per share.
• Both the RSUs and stock options were granted on December 22, 2025.
• The RSUs vest over four years from the grant date in substantially equal quarterly installments, contingent on continued service.
• The stock options vest over four years from the grant date in substantially equal monthly installments, contingent on continued service, and expire on December 21, 2033.
• Following these transactions, Mr. Zalevsky beneficially owns 25,221 shares of common stock and 25,000 stock options directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation grant, which is generally a neutral to slightly positive event as it aims to align management incentives with long-term company performance, though it introduces potential future dilution.

Positives

• Incentivizes the Chief R&D Officer, Jonathan Zalevsky, to remain with Nektar Therapeutics and contribute to long-term company performance through a four-year vesting schedule.
• Aligns management's interests with those of shareholders by linking compensation to future stock performance.
• The grant of RSUs at a $0 price provides a direct equity stake, while stock options offer upside potential.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders when RSUs vest and options are exercised.

Risks

• Future stock price fluctuations could impact the value of the granted awards for the reporting person.
• Potential dilution of existing shareholder value upon vesting and exercise of the equity awards.
• The value of the stock options is contingent on the company's stock price exceeding the exercise price of $43.48.

Future Outlook

The long-term vesting schedule for both RSUs and stock options, extending over four years, indicates an expectation of continued service from the Chief R&D Officer and a strategic alignment of his incentives with the company's long-term performance goals.

Industry Context

Executive equity grants, such as RSUs and stock options, are a standard component of compensation packages in the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key talent like Chief R&D Officers. These awards typically vest over several years to ensure long-term commitment and align executive interests with shareholder value creation.

Comparison to Industry Standards

• The use of both Restricted Stock Units (RSUs) and stock options is a common practice in executive compensation across the biotech and tech sectors, similar to companies like Amgen or Gilead Sciences, which often use a mix of equity vehicles to balance retention and performance incentives.
• A four-year vesting schedule for equity awards is standard in the industry, comparable to practices at companies such as Pfizer or Merck, ensuring long-term commitment from key executives.
• The grant of RSUs at a $0 price is typical for such awards, representing a direct equity stake, while stock options with a specific exercise price are designed to reward future stock appreciation, a common feature in growth-oriented industries.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of equity awards; however, the awards are intended to incentivize management, potentially leading to increased shareholder value over the long term.
• Employees (specifically Jonathan Zalevsky): Significant long-term incentive and retention mechanism, aligning personal financial interests with company performance.

Next Steps

• Continued vesting of 6,250 Restricted Stock Units in quarterly installments over four years from December 22, 2025.
• Continued vesting of 25,000 stock options in monthly installments over four years from December 22, 2025.
• Potential exercise of stock options by December 21, 2033, if the stock price exceeds $43.48.

Key Dates

Keywords

Nektar Therapeutics, NKTR, Jonathan Zalevsky, Chief R&D Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Vesting, Rule 10b5-1